Improving Human And Environmental Health Articles & Analysis: Older
55 news found
EMOTIV, the bioinformatics pioneer advancing understanding of the human brain using electroencephalography (EEG), today added two renowned scientists to its executive leadership team, naming Dr. Gary William Flake as Chief Technology Officer (CTO) and Dr. Scott Rickard as Chief AI Scientist. The new hires underscore EMOTIV’s strategic objectives to meet the quickening pace of advancements ...
The World Social Report 2023 calls for concrete measures to support an aging global population in the face of rising pension and health care costs. According to a study published by the United Nations Department of Economic and Social Affairs, population aging is the defining global trend of our time. Countries can benefit by promoting equality of opportunity from birth, so that everyone has the ...
Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role that microbial communities play in maintaining human health. However, analyzing the vast amounts of data generated by high-throughput sequencing of microbiome samples can be a daunting task. ...
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in the clinical ...
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, zuranolone, on Tuesday, December 6 at 8:00 a.m. ET. Zuranolone is being evaluated as a potential rapid-acting, once-daily, oral two-week treatment for major ...
bydney, Australia - November n, lull — Kaaiopnarm I neranostics (A:>a:kauj, a aeveioper or a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce agreement with Australia's Nuclear Science and Technology Organisation (ANSTO) to supply the Company with isotope non-carrier-added lutetium-177 (Lu-177) for its trials in ...
Synbiotic Health, a market leader in the discovery, development, and commercialization of probiotic ingredients, announced that the company has expanded its R&D and commercial capabilities with the acquisition of a 43,000 sf facility in Madison, Wisconsin. The new facility is dedicated to the development and commercialization of advanced probiotic ingredients for improved health. The Madison ...
LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. LYTGOBI previously received breakthrough, orphan drug ...
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder (MDD) and postpartum depression. The 11 new analyses are being presented at the 2022 Psych Congress in New Orleans, ...
Results from the primary analysis of the SUNLIGHT trial to be presented at an upcoming scientific conference Paris - September 12, 2022– Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival ...
Celdara Medical, LLC today announced that the National Institute of Aging’s Research and Entrepreneurial Development Immersion (REDI) initiative has awarded an R25 Entrepreneurship Enhancement Award to fund the company’s comprehensive training program focused on Alzheimer’s Disease: the Alzheimer’s-focused Celdara Medical High-Potential Entrepreneurs’ Fellowship ...
Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417 Cullinan Oncology will receive an upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone payments Cullinan Oncology and Taiho will equally share ...
PRINCETON, N.J., MARCH 30, 2022 – Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for futibatinib in the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) harboringFGFR2 gene rearrangements, including ...
MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation for providing reliable de novo sequencing, genotyping, microarray, and bioinformatics services. With years of experience in the pharmaceutical and life science sectors, CD Genomics has announced Microbial Transcriptomics ...
February 22, 2022 – Celdara Medical, LLC today announced that alumni of their DRIVEN Partnership Program have collectively surpassed $50M in follow-on funding. DRIVEN was established in 2018 as the Northeast’s NIH-funded Accelerator Hub. Led by Celdara Medical and Simbex, it has always had a singular goal: improve human health by increasing the number, quality, and success rate of ...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors. The funds will be used to advance the company’s pioneering drug discovery ...
Microbiome-based ingredient company Synbiotic Health announces that Kevin Hooper has joined the company as Director of Business Development. Hooper has more than 14 years’ experience in sales and business development, most recently at the global ingredient supplier IFF Health. At Synbiotic Health he will work with Steve Prescott, Senior Vice President of Business Development, to implement ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce it has signed a Global Master Services Agreement with My Next Health (“MNH”), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit. My Next Health Inc. (“MNH”) is the ...